Compare Devon Energy Corp (DVN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Mesoblast Limited — how do they compare? Devon Energy Corp trades at $48.51 (market cap $53.81B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Devon Energy Corp is far larger — about 30.7× Mesoblast Limited's market cap, and Devon Energy Corp pays a 2.62% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Mesoblast Limited for 14 Days on average.
| DVN | MESO | |
|---|---|---|
Market Cap | $53.81B | $1.75B |
Volume | 11,556,740 | 239,027 |
Sector | Energy | Health |
52-Week High | $52.07 | $20.96 |
52-Week Low | $31.74 | $13.19 |
Typical Hold Time | 136 Days | 14 Days |
Enterprise Value | $64.55B | $1.83B |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $47.88, down 0.29% with a bullish technical signal from moving averages. The company shows solid fundamentals with a P/E of 10.41 and net margin of 16.67%, though revenue declined from $19.2B in 2022 to $17.2B in 2025. Recent news highlights activist investor pressure for strategic alternatives and potential asset sales, while analyst consensus remains strongly bullish with a $62.40 price target representing 30% upside.
DVN presents a compelling value opportunity with attractive valuation metrics and strong cash flow generation. However, investors face risks from oil price volatility, execution challenges in asset sales, and competitive pressures in the shale sector. The company's Permian Basin focus and potential strategic moves provide catalysts, but macroeconomic headwinds could impact near-term performance.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
